CAMP4 Therapeutics Corporation
NASDAQ:CAMPBiotechnology
Healthcare
$4.00 +2.42%
+$0.10 today
- Market cap
- $251.02M
- Beta
- 0.08
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.49
52W Low $1.31High $7.75
Volume 0.21M
Average 0.10M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$29.55M
FY 2025 · Annual
Investing Cash Flow
-$243,000.00
FY 2025 · Annual
Financing Cash Flow
$75.89M
FY 2025 · Annual
+5.9% YoYCash Flow Statement
USD
Metric | FY2021 Feb 2022 | FY2022 Feb 2023 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.99M) | (44.19M) | (49.29M) | (51.79M) | (80.4M) |
| Depreciation & Amortization | 22.8M | 878K | 1.68M | 1.7M | 1.64M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.32M | 1.38M | 2.91M | 4.03M | 4M |
| Change in Working Capital | 1.59M | 373K | (154K) | (1.88M) | 13.01M |
| Accounts Receivables | 1.44M | 0 | 0 | 0 | 0 |
| Inventory | 5.16M | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | (1.03M) |
| Other Working Capital | (5.01M) | 373K | (154K) | (1.88M) | 14.04M |
| Other Non-Cash Items | (11.94M) | 3.02M | 705K | 2.39M | 32.21M |
| Operating Cash Flow | (4.22M) | (38.54M) | (44.16M) | (45.56M) | (29.55M) |
| Capital Expenditures | (13.3M) | (4.03M) | (678K) | (441K) | (279K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 36K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 5.72M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (7.58M) | (4.03M) | (678K) | (441K) | (243K) |
| Debt Repayment | — | (93K) | 116K | (824K) | (208K) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.64M) | 100.25M | 185K | 72.49M | 14.93M |
| Financing Cash Flow | (2.64M) | 100.16M | 301K | 71.66M | 75.89M |
| Effect of Forex Changes | (965K) | 25.6M | 0 | 0 | 0 |
| Net Change in Cash | (15.4M) | 83.19M | (44.53M) | 25.66M | 46.09M |
| Free Cash Flow | (17.52M) | (42.57M) | (44.83M) | (46M) | (29.83M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$80.4M
+ D&A$1.6M
+ Stock-Based Comp$4.0M
+ Deferred Tax$0
+ Working Capital$13.0M
+ Other Non-Cash$32.2M
= Operating Cash Flow-$29.6M
- Capex-$279.0K
= Free Cash Flow-$29.8M
Analysis
FY2025 free cash flow is -$29.8M. FCF conversion is 37.1% of net income. Operating cash flow was -$29.6M, with capex of -$279.0K. The largest bridge item is Other Non-Cash at $32.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 8-K | Current report | Nov 5, 2026 |
Does CAMP generate free cash flow?
CAMP4 Therapeutics Corporation (CAMP) generated -$29.83M of free cash flow in fiscal 2025.
How much operating cash flow does CAMP produce?
Operating cash flow was -$29.55M, before capital expenditures of $279,000.00.
Continue the stock analysis
Jump to another research area for this company.